Faronilla R&D päivä tulossa 16. kesäkuuta. Tuossa ei nopealla lukemisella ainakaan sanota, että se olisi vain yrityksille tai suurille investoijille. Yritän ilmoittautua mukaan.
Faron announces R&D Day to be held in June
Company announcement, 28 May 2020 at 9.00 AM (EET)
TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to host a virtual R&D Day via webcast on Tuesday, 16 June 2020 at 3pm EEST, 1pm BST, 8am EDT.
The event will provide an opportunity for the Company’s management team to present its R&D strategy and provide insight into Faron’s two clinical stage programmes. Management will discuss the Company’s wholly-owned novel precision cancer immunotherapy, Clevegen, targeting Clever-1 positive tumour associated macrophages (TAMs) in selected metastatic or inoperable solid tumours, currently under development in the ongoing phase I/II MATINS clinical trial. Management will also discuss Traumakine, for the treatment of patients with Acute Respiratory Distress Syndrome (ARDS), which is currently being investigated in COVID-19 patients in the ongoing REMAP-CAP trial and the WHO’s Solidarity trial. There will be an opportunity to ask questions during the webcast.
For further information on the R&D Day, or to register for the event, please contact Consilium Strategic Communications at email@example.com